Oliver Curme is a retired venture capitalist. From 1985 to 2005 he worked for Battery Ventures focusing on computer and software investments. In 2006 he helped to found Tiandi Capital in Shanghai, a venture capital firm focusing on cleantech investments in China. He has also personally invested in a number of biotech and medtech investments, including Wuxi Pharmatech. Ollie has an MBA from Harvard Business School and an Sc.B. in Biochemistry from Brown University.

Rob Graifman is Principal, Thylacine Capital as well as a serial entrepreneur and early stage investor.

Chairman of the Board and Acting CEO; Managing Director, Walter Greenblatt & Associates: Walter founded WG&A in 1998 focused solely on early stage life science companies. Since 2002, the firm has raised $122M in seed and Series A round capital for early stage lifescience companies and returned, to date, $622M to investors in those rounds. An experienced entrepreneur and “hands-on” operating executive, Walter has founded and grown to profitability a series of successful operating businesses. Earlier in his career he worked as a strategic consultant at Bain & Company in a variety of industries in including healthcare. Walter holds an BS from Yale University, an MA from Oxford University and an MBA from Harvard Business School.

Shay is an experienced entrepreneur and investor. Shay is the Managing Partner of Greenfield Partners- a technology Investment Fund focused on Growth stage technology companies. Shay is also a senior advisor to TPG Growth- A Private Equity fund based in San Francisco. Prior to that, Shay was the CEO of Illuminare Biotechnologies and Managing Director of Thylacine Capital, a family office investing in technology and real estate. Shay holds a B.A. from Fairleigh Dickinson University and EMBA from Columbia Business School.